Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management Webcast (2024)

This is a tumor board-style course, with case presentations ranging from low-risk disease with conservative management to high-risk and metastatic disease requiring multidisciplinary management, that will highlight key issues in the care of patients with upper tract urothelial carcinoma (UTUC) and incorporate the AUA UTUC Guidelines. A multidisciplinary faculty panel will discuss their recommendations and their rationale. Key aspects that will be covered include: • Adequate staging, endoscopic evaluation and risk stratification with clinically validated tools. • Evaluating renal function before surgery and estimating post-nephroureterectomy function as part of the preoperative planning. • Exploring the data from clinical trials of a novel chemotherapy gel, intravesical chemotherapy, neoadjuvant chemotherapy, adjuvant chemotherapy, chemotherapy for metastatic disease and role of immunotherapy. • Evaluation of patients for Lynch syndrome, and identifying methods for screening and testing. • Role of surgical consolidation for metastatic UTUC.


This educational activity is supported by independent educational grants from:

Merck & Co., Inc., UroGen Pharma, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify clinically available data that can help assess risk of UTUC disease.
  2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate.
  3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy.
  4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes.
  5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Cole, SuzanneNothing to Disclose  
Feldman, Adam S.Olympus America, IncConsultant or AdvisorCurrent
Vessi MedicalConsultant or AdvisorCurrent
UroGen PharmaConsultant or AdvisorCurrent
Progenics Pharmaceuticals, Inc.Consultant or Advisor01/22/2023
ScentientStock Option09/04/2023
Matin, Surena FazeliJohnson&JohnsonConsultant or Advisor05/16/2023
MerckConsultant or AdvisorCurrent
FujifilmConsultant or Advisor12/15/2023



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.